BioStock: Medivir clears key hurdles ahead of phase IIb

While currently conducting a rights issue, Medivir has rapidly progressed the development of the drug candidate fostrox for the treatment of liver cancer. Firstly, they have completed the development of an updated formulation of fostrox suitable for commercial manufacture. Additionally, they have secured agreements for the manufacturing of fostrox GMP substance for clinical trials. The goal is to expedite necessary activities to initiate a pivotal phase IIb study in 2024, with the aim of accelerated approval in 2027.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/medivir-clears-key-hurdles-ahead-of-phase-iib/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/